DermBiont, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.dermbiont.com
Clinical Trials
13
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Randomized Study Using SM-030 Gel for Adults With Melasma
- Conditions
- Melasma
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- DermBiont, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT06454747
- Locations
- 🇸🇻
Centro de Investigación y Desarrollo Brioso Ramirez, Santa Tecla, La Libertad, El Salvador, El Salvador
🇸🇻Zepeda Dermatologia, Santa Tecla, La Libertad, El Salvador
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers
- Conditions
- Non-Melanoma Skin Cancers
- Interventions
- Drug: SM-020 1% Gel
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- DermBiont, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06409195
- Locations
- 🇺🇸
Dermatology, Laser and Vein Specialist, Charlotte, North Carolina, United States
A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis
- Conditions
- Seborrheic Keratosis
- Interventions
- Drug: SM-020 gel 1.0%Drug: Vehicle gel
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- DermBiont, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06108024
- Locations
- 🇺🇸
Driven Research LLC, Coral Gables, Florida, United States
🇺🇸Minnesota Clinical Study Center, New Brighton, Minnesota, United States
🇺🇸Oregon Medical Research Center, Portland, Oregon, United States
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Dermatosis Papulosa Nigra (DPN)
- Conditions
- Dermatosis Papulosa Nigra
- Interventions
- Drug: SM-020 gel 1.0%
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- DermBiont, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06099080
- Locations
- 🇺🇸
Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California, United States
Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos
- Conditions
- Hyperpigmentation
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- DermBiont, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05511948
- Locations
- 🇸🇻
Zepeda Dermatologia, Santa Tecla, La Libertad, El Salvador
- Prev
- 1
- 2
- 3
- Next